JP2022554186A - 造影および処置のためのフィブリン結合化合物 - Google Patents

造影および処置のためのフィブリン結合化合物 Download PDF

Info

Publication number
JP2022554186A
JP2022554186A JP2022524083A JP2022524083A JP2022554186A JP 2022554186 A JP2022554186 A JP 2022554186A JP 2022524083 A JP2022524083 A JP 2022524083A JP 2022524083 A JP2022524083 A JP 2022524083A JP 2022554186 A JP2022554186 A JP 2022554186A
Authority
JP
Japan
Prior art keywords
compound
fibrin
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022524083A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554186A5 (https=
Inventor
ピーター キャラバン
トーマス ジェイ． マクマリー
リチャード ジェイ． ルービー
Original Assignee
コラジェン メディカル リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コラジェン メディカル リミテッド ライアビリティ カンパニー filed Critical コラジェン メディカル リミテッド ライアビリティ カンパニー
Publication of JP2022554186A publication Critical patent/JP2022554186A/ja
Publication of JP2022554186A5 publication Critical patent/JP2022554186A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022524083A 2019-10-23 2020-10-23 造影および処置のためのフィブリン結合化合物 Pending JP2022554186A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924997P 2019-10-23 2019-10-23
US62/924,997 2019-10-23
PCT/US2020/057198 WO2021081430A1 (en) 2019-10-23 2020-10-23 Fibrin-binding compounds for imaging and treatment

Publications (2)

Publication Number Publication Date
JP2022554186A true JP2022554186A (ja) 2022-12-28
JP2022554186A5 JP2022554186A5 (https=) 2023-10-26

Family

ID=75620290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524083A Pending JP2022554186A (ja) 2019-10-23 2020-10-23 造影および処置のためのフィブリン結合化合物

Country Status (6)

Country Link
US (1) US20240115744A1 (https=)
EP (1) EP4048324A4 (https=)
JP (1) JP2022554186A (https=)
KR (1) KR20220104703A (https=)
CN (1) CN114945388B (https=)
WO (1) WO2021081430A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202313965D0 (en) * 2023-09-13 2023-10-25 Univ Oxford Innovation Ltd Radiopharmaceutical

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536875A (ja) * 2001-07-30 2004-12-09 エピックス メディカル， インコーポレイテッド ペプチドに基づく多量体標的化造影剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001415A2 (en) * 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
WO2007047608A2 (en) * 2005-10-14 2007-04-26 Epix Pharmaceuticals, Inc. Fibrin targeted therapeutics
CN101558081B (zh) * 2006-12-11 2014-08-20 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
PL2187965T3 (pl) * 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
WO2015038968A1 (en) * 2013-09-13 2015-03-19 The General Hospital Corporation Activatable fibrin-binding probes
US20190216956A1 (en) * 2016-07-27 2019-07-18 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses thereof
US20190247520A1 (en) * 2018-01-24 2019-08-15 Carl A. Morris Non-invasive detection of disease progression and therapeutic efficacy for muscular dystrophies and diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536875A (ja) * 2001-07-30 2004-12-09 エピックス メディカル， インコーポレイテッド ペプチドに基づく多量体標的化造影剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 60, JPN6024033241, 2017, pages 286 - 293, ISSN: 0005602018 *
MOLECULAR PHARMACEUTICS, vol. 10, JPN6024033244, 2013, pages 4309 - 4321, ISSN: 0005602016 *
MOLECULAR PHARMACEUTICS, vol. 12, JPN6024033242, 2015, pages 1921 - 1928, ISSN: 0005602017 *

Also Published As

Publication number Publication date
CN114945388A (zh) 2022-08-26
EP4048324A1 (en) 2022-08-31
WO2021081430A1 (en) 2021-04-29
EP4048324A4 (en) 2024-05-15
US20240115744A1 (en) 2024-04-11
KR20220104703A (ko) 2022-07-26
CN114945388B (zh) 2025-03-18

Similar Documents

Publication Publication Date Title
JP7515023B2 (ja) 二重標的化化合物及びその調製方法と応用
CA2452923C (en) Peptide-based compounds for targeting integrin receptors
JP5784911B2 (ja) ボンベシンアナログペプチドアンタゴニスト複合体
JP5308829B2 (ja) 癌の画像化および処置
CN116474108A (zh) 成纤维细胞活化蛋白(fap)-靶向成像和治疗
PT1853605E (pt) Ligandos sintéticos direccionados para integrinas para aplicações em diagnóstico e terapêutica
CN101537190A (zh) 肽基化合物
AU2018363807A1 (en) A double-labeled probe for molecular imaging and use thereof
AU2018373675A1 (en) A double-labeled probe for molecular imaging and use thereof
CN110312517A (zh) 促黄体激素释放激素受体(lhrh-r)缀合物及其用途
JPWO2013081091A1 (ja) 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤
CN102076214A (zh) 释放胃泌素的肽化合物
JP2001506583A (ja) テクニチウム―９９ｍ標識キレーターが組み込まれた環状ペプチド
JP2022554186A (ja) 造影および処置のためのフィブリン結合化合物
KR20080022588A (ko) 영상화제로서의 히드라지드 컨쥬게이트
JP2006517539A (ja) 造影剤
KR20130024963A (ko) 개선된 ｎ4 킬레이트제 결합체
JP2002527450A (ja) 画像形成試薬としてのキレーターが組み込まれたＡｒｇ−Ｇｌｙ−Ａｓｐ（ＲＧＤ）ミメティック合成ディスインテグリン類
HK40078955A (en) Fibrin-binding compounds for imaging and treatment
KR101551232B1 (ko) Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물
JP2005068046A (ja) ソマトスタチンアナログ誘導体およびその利用
WO2025171887A1 (en) Radiolabeled complexes and pharmaceutical compositions including the same
TW202535356A (zh) 神經肽y1受體(npy1r)靶向治療劑及其用途
WO2026027771A1 (en) Alpha v beta 6-integrin binding cyclopeptides with non-natural amino acids, and conjugates thereof
JP2023516878A (ja) 同位体標識された選択的ｃｘｃｒ４結合性ペプチドコンジュゲート並びにその作製方法及び使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220623

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260330

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260424